Clinical Trial Update: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating dual 64Cu-DOTATATE and 18F-FDG PET/CT imaging for neuroendocrine neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma Metastatic
• Neuroendocrine Tumors

Drugs mentioned

• 18F-FDG (fluorodeoxyglucose F-18)
• 64Cu-DOTATATE (Copper-64 DOTATATE)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: GEP-NET, Neuroendocrine Tumors | Phase 2 | Status: UNKNOWN